Participants
leukemia or pancreatic cancer
A total of 379 patients were screened using the EHR, 94 patients met criteria and were approached in clinic with 59% (55/94) agreeing to POC HbA1c testing. Primary reasons for study exclusion during prescreening included life expectancy ≤2 years and patients diagnosed with leukemia or pancreatic cancer (16.9%), current use or inability to tolerate metformin (14.8%), and abnormal labs that contraindicated metformin use (eGFR, AST/ALT) (13.9%). No significant demographic differences were noted between patients that agreed versus patients that declined to participate (Table Baseline characteristics among patients screened in clinic.
